Previous close | 37.00 |
Open | N/A |
Bid | 56.75 |
Ask | 61.75 |
Strike | 175.00 |
Expiry date | 2025-03-21 |
Day's range | 37.00 - 37.00 |
Contract range | N/A |
Volume | |
Open interest | 26 |
The Committee for Medicinal Products for Human Use recommends marketing authorization for Moderna's updated mRNA COVID-19 jab, Spikevax.
Despite becoming one a household name during the pandemic, Moderna stock has mostly fallen over the past three years amid slow sales.
The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.